Search Results 421-430 of 16063 for pharmacogenetics
The median survival is about 5 months from time of diagnosis. A Mayo Clinic-led study, published in the journal Science Translational Medicine , reveals the ...
The purpose of this study is to characterize TRPC6 risk variants for doxorubicin-related cardiotoxicity in prospectively collected samples from breast ...
Drug repurposing to expand treatment options for patients leaps forward with an advance in machine learning from Mayo Clinic researchers and collaborators. Led ...
The purpose of this study is to validate candidate universal and site-specific methylated DNA markers (MDMs) in DNA extracted from formalin-fixed paraffin ...
These factors include where someone lives, household income, access to healthy food and availability of transportation. If you have cancer, social determinants ...
View patient resources recommended by the Immuno-Epigenetics Lab led by William A. Faubion Jr., M.D., at Mayo Clinic's campus in Minnesota.
The purpose of this study is to determine the baseline chronotype patterns (with Morningness-Eveningness Questionnaire (MEQ) ) among inpatients with Major ...
Mayo Clinic healthcare professionals have access to the most advanced systems for diagnosing and treating heart rhythm problems.
Rochester, Minn. This is a randomized Phase 2 study of novel SEQUEnced immunotherapy (pembrolizumab) with anti-angiogenesis and chemotherapy in advanced gastric ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.